Shots:

• The P-III (YOSEMITE/ RHINE & Archway) studies evaluate Vabysmo & Susvimo in 1,891 (YOSEMITE & RHINE) & 415 (Archway) for IV use via ocular implant in patients with DME & AMD, respectively
• In (YOSEMITE & RHINE) studies, 60% & 64.5% achieved q4mos. dosing @2yrs., 80% of patients could extend treatment to q3mos. @2yrs., 42.8% & 44.3% achieved a two-step improvement from baseline along with 51.4% & 53.5% improvement in diabetic retinopathy severity. In the Archway study, 95% of susvimo patients maintained a 6mos. treatment @2yrs.
• In all studies with longer follow-up, Vabysmo & Susvimo was well tolerated with favorable benefit-risk profiles & the safety will be monitored closely in the post-market setting

Ref: Businesswire | Image: Clinical Trial Arena